Effects, risks, and legal status vary
It is our most popular option for patients whose primary goal is injury repair, faster recovery, or reducing chronic pain and inflammation
Linalool, D-limonene, zingiberene, and other phytoconstituents found in EOs have the potential to be useful components for reducing MASLD through lipid-modulating, anti-inflammatory, and antioxidant mechanisms
Effective April 22, 2026, BPC-157 was removed from Category 2 (the bulks substances list flagged as raising significant safety concerns)
Compounded by a licensed 503A pharmacy
The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma